Additionally, the development of improved monoclonal antibodies targeting molecules involved in the trafficking of MM, CLL, and ALL cells, such as CXCR4, CD44, SLAMF7/CS1, and CCR9 might open new opportunities for clinical treatments against these hematologic malignancies. This evidence concerns the gene CCR9 and acute lymphoblastic leukemia.